申请人:Schiene-Fischer Cordelia
公开号:US20100160175A1
公开(公告)日:2010-06-24
The present invention is based on the finding that the cis/trans isomerisation of secondary amide peptide bonds in oligo- and polypeptides can be catalytically promoted. This catalysis is effected by enzymes which are hereinafter called “secondary amide peptide bond cis/trans isomerases (APIases). It can be assumed that the APIase activity plays a central role in a number of pathophysiological processes. Thus, the invention relates to pharmaceutical compositions comprising substances which inhibit APIase activity.
本发明基于以下发现:可以通过催化促进二级酰胺肽键在寡肽和多肽中的顺反异构化。这种催化作用是通过酶实现的,后者在此称为“二级酰胺肽键顺反异构酶(APIase)”。可以认为APIase活性在许多病理生理过程中起着核心作用。因此,本发明涉及包含抑制APIase活性的物质的制药组合物。